AbbVie 2013 Annual Report Download - page 5
Download and view the complete annual report
Please find page 5 of the 2013 AbbVie annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.-
1 -
2 -
3 -
4 -
5 -
6 -
7 -
8 -
9 -
10 -
11 -
12 -
13 -
14 -
15 -
16 -
17
-
18
-
19
-
20
-
21
-
22
-
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
32
-
33
-
34
-
35
-
36
-
37
-
38
-
39
-
40
-
41
-
42
-
43
-
44
-
45
-
46
-
47
-
48
-
49
-
50
-
51
-
52
-
53
-
54
-
55
-
56
-
57
-
58
-
59
-
60
-
61
-
62
-
63
-
64
-
65
-
66
-
67
-
68
-
69
-
70
-
71
-
72
-
73
-
74
-
75
-
76
-
77
-
78
-
79
-
80
-
81
-
82
-
83
-
84
-
85
-
86
-
87
-
88
-
89
-
90
-
91
-
92
-
93
-
94
-
95
-
96
-
97
-
98
-
99
-
100
-
101
-
102
-
103
-
104
-
105
-
106
-
107
-
108
-
109
-
110
-
111
-
112
-
113
-
114
-
115
-
116
-
117
-
118
-
119
-
120
-
121
-
122
-
123
-
124
-
125
-
126
-
127
-
128
-
129
-
130
-
131
-
132
-
133
-
134
-
135
-
136
-
137
-
138
-
139
-
140
-
141
-
142
-
143
-
144
-
145
-
146
-
147
-
148
-
149
-
150
-
151
-
152
-
153
-
154
-
155
-
156
-
157
-
158
-
159
-
160
-
161
-
162
-
163
-
164
-
165
-
166
-
167
-
168
-
169
-
170
-
171
-
172
-
173
-
174
-
175
-
176
 |
 |
PART I
ITEM 1. BUSINESS
Separation from Abbott Laboratories
On January 1, 2013, AbbVie(1) became an independent company as a result of the distribution by
Abbott Laboratories (Abbott) of 100 percent of the outstanding common stock of AbbVie to Abbott’s
shareholders. Each Abbott shareholder of record as of the close of business on December 12, 2012 (the
Record Date) received one share of AbbVie common stock for each Abbott common share held as of
the Record Date.
AbbVie was incorporated in Delaware on April 10, 2012 to hold Abbott’s former research-based
pharmaceuticals business. AbbVie’s common stock began trading ‘‘regular-way’’ under the ticker symbol
‘‘ABBV’’ on the New York Stock Exchange on January 2, 2013.
Overview
AbbVie is a global, research-based biopharmaceutical company. AbbVie develops and markets
advanced therapies that address some of the world’s most complex and serious diseases. AbbVie’s
products are focused on treating conditions such as chronic autoimmune diseases, including rheumatoid
arthritis, psoriasis, and Crohn’s disease; low testosterone; HIV; endometriosis; thyroid disease;
Parkinson’s disease; and complications associated with chronic kidney disease and cystic fibrosis, among
other health conditions. AbbVie’s pipeline of promising new medicines includes more than 20
compounds or indications in Phase II or Phase III development across such important medical
specialties as immunology, virology, oncology, renal disease, neurological diseases and women’s health.
Segments
AbbVie operates in one business segment—pharmaceutical products. Incorporated herein by
reference is Note 14 entitled ‘‘Segment and Geographic Area Information’’ of the Notes to
Consolidated Financial Statements included under Item 8, ‘‘Financial Statements and Supplementary
Data’’ and the sales information related to HUMIRA included under ‘‘Results of Operations.’’
Products
AbbVie’s portfolio of products includes a broad line of therapies that address some of the world’s
most complex and serious diseases.
(1) As used throughout the text of this report on Form 10-K, the term ‘‘AbbVie’’ refers to
AbbVie Inc., a Delaware corporation, or AbbVie Inc. and its consolidated subsidiaries, as the
context requires.
1